We believe that we can change the monoclonal antibody development in most casee even if you have a target that seems impossible.
This technology was patented in 2007 and from that point on the company had two main characteristics: developing custom made antibodies and developing transgenic animals.
Our goal is to support R&D of pharma companies and academics to improve their efficiency in identifying new therapeutic targets and therapeutic candidates.
